Aya Helali MD PhD

Tumour-agnostic therapies are accelerating, but implementation is lagging behind science. Looking forward to discussing where the real gaps are at this upcoming @myESMO Therapeutic Landscapes webinar. @AyaHelali @BenWestphalen @dcorreiamartins @StefanMichiels @OncoAlert

Thx @ErulEnes for spotlighting #ISLB2025's stakeholder discussions! Key takeaways: the integration of AI may revolutionise liquid biopsy, integrating multi-omics for real-time tumor tracking and treatment modification. #PrecisionMedicine #MRD #liquidbiopsy @hkumed

🚨Our @CellReports study reveals how #ecDNA acts as a "rogue amplifier" in #GBM tumors Massive thanks to collaborators #HongKongGenomeInstitute and the team @hkumed. Most importantly, we're grateful to patients who made this possible. sciencedirect.com/science/articl…

Just back from #ESMO25! 🧠⚡️ Latest in #glioma Rx: - SCOUT trial’s “watch-and-see” #NTRK inhibitor approach (challenge: when to pause?) - IL13Ra2 #CART cells – progress but TME/antigen escape hurdles - Procaspase 3: apoptosis revival? 🔥 #NeuroOncology @hkumed @myESMO

🔬 Key findings: 1️⃣ #ecDNA supercharges oncogenes (EGFR/PDGFRA),creating aggressive tumor subtypes 2️⃣ Complex #EGFR ecDNA=worse survival (new prognostic marker?) 3️⃣ Epigenetic "lock" traps tumors in therapy-resistant states 4️⃣ Rewired immune microenvironment supports tumor growth

What an absolute pleasure to share that stage with you all at #WCLC25 @IASLC @CespedesMontse @HaradaGuilherme @MaraverLab @triparnasen 💫

Prof @AyaHelali -precautions/pitfalls in reporting exploratory biomarker analyses (No single guideline addresses this); Prof @herbloong increasing importance of PROs in early phase clin trials incl dose esc decisions-it’s complicated! #ESMOTATAsia25 @myESMO

Also had the opportunity to highlight our @CUHKMedicine @hkumed study that was published in @myESMO @ESMO_Open some years ago look at #comorbidities of patients w/ #sarcomas. We have identified that 10% of #newly diagnosed #sarcoma patients in #hongkong had #DiabetesMellitus, 5% w/ history of #CVA and 4% w/ #IHD. More co-morbidities associated with poorer prognosis and survival, independent of age. There maybe a role for #GPs and #primarycare colleagues to be more involved in #earlydetection and #identification of #atrisk individuals. @CarlosWongHKU

Thanks @RTHK_HK for giving me the opportunity to #introduce and #discuss #SoftTissue #sarcomas to the wider community. A group of #rarediseases which benefits from #awareness and #specialistcare #sarcomaawarenessmonth #CUHKSarcoma @CUHKMedicine @ctosociety #CTOSTweeTOS Recording in Cantonese: rthk.hk/radio/radio1/p…

Hot off the press! Our commentary exploring the potential of Adv-mSS, a dual-targeting oncolytic adenovirus. This innovation supercharges TAMs and CD8 T-cells, delivering a one-two punch to cancer. @hkumed @jitcancer @MarcLecoultre jitc.bmj.com/content/13/6/e…

📣 Join us in Hong Kong for a chance to contribute to oncology drug development in Asia Pacific! ⏰ Late registration deadline: 18 June 🔗 ow.ly/MWyG50W90Ef @herbloong @TonyMok9 @DrBenTran @AyaHelali

Newly published ESMO recommendations provide roadmap for the implementation of molecular tumour boards in clinical practice. Discover the key focus areas to optimise #PrecisionOncology Read via #ESMODailyReporter: ow.ly/mexL50VvtUM @BenWestphalen @Annals_Oncology

Thank you to all the investigators for their extraordinary efforts in shaping the MTB consensus statements. 🙌 Under the outstanding leadership of @curijoey and @BenWestphalen, this collaborative achievement sets a new benchmark for the field🚀 Bravo to the entire team!

📢 Just published in Annals of Oncology: “ESMO Precision Oncology Working Group Recommendations on the Structure and Quality Indicators for Molecular Tumour Boards in Clinical Practice”. sciencedirect.com/science/articl… @BenWestphalen @myESMO

Looking forward to seeing everyone in #HongKong at #ESMOTATAsia25

Thank you @myESMO for the invite and my honor to contribute ! And so happy to work with a great GU team! @ravikanesvaran @DrIacovelli @Ecastromarcos @RenuEapen @nachoduranm @Marnizasaad

It’s just incredible to be part of this community of talented and supportive colleagues in #HongKong #esmoasia2024 @myESMO

@HPrenen #ESMO24 concomitant paper: @DocSacher presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium @HPrenen

⭐️Wow ! Blown away by the phenomenal discussion on MTAP & PRMT5 inhibitors by @CKadoch @DanaFarber @DrChoueiri @myESMO #ESMO24 #ESMOAmbassadors